Mass-based drug screening shows promise for personalized chemotherapy

A phase II clinical trial demonstrates the feasibility of mass-based response testing (MRT) in tailoring intraperitoneal chemotherapy for patients with unresectable appendiceal or colorectal peritoneal metastases. MRT assessed tumor susceptibility to various HIPEC drug regimens, offering a personalized approach to treatment. The study aims to improve outcomes by personalizing regimens based on patient-specific sensitivities, thereby addressing the inconsistencies in HIPEC efficacy seen in previous trials. Results will guide future research on MRT-selected regimens.